Return to Europe for the 2nd IMPACCT Real World Evidence Summit 2025

R&D
2nd IMPACCT Real World Evidence Summit Europe

The IMPACCT Real World Evidence Summit is back, offering the opportunity to bring together 50+ pharma RWE decision makers to discuss integrated evidence plans, data sharing optimization, infrastructure, expertise, and aligning statistical methods with regulatory expectations to enhance ECA study credibility. With a stellar line-up of industry-leading speakers, here’s a snapshot of who you could meet:

  • Lill-Brith Wium von Arx, RWE Northern Europe Hub Lead, Eli Lilly and Company
  • Lene Hammer-Helmich, Director, Head of Real-World Evidence & Epidemiology, Lundbeck
  • Maurice Timmermans, Head Procurement Real World Evidence Generation & Dissemination, Astellas Pharma
  • Elena Panitti, Global Director Evidence Valuation and Enablement, Novartis
  • Marcus Lawrance, Director – Global Oncology & Data Strategy, Astra Zeneca
  • Joan Mendivil, Head Evidence & Outcomes Research, Pharvaris

Key highlights include:

  • Engage with 50+ pharma RWE decision makersto discuss integrated evidence plans, data sharing optimization, infrastructure, expertise, and aligning statistical methods with regulatory expectations to enhance ECA study credibility.
  • Actionable takeaways on drastically improving data quality and end-to-end insights both from clinical research RWE experts and HEOR, value and access RWE experts.
  • Panel Discussions on the importance of effectively collaborating with DARWIN and optimizing patient reported outcomes to gather real-time feedback on patient experiences and treatment effectiveness in real-world settings.
  • 6+ hours of networkingto connect with industry experts - facilitate meaningful exchanges of insights and collaborative opportunities.

For full event details, speaker faculty and speaker breakdowns download the event guide today.

Link: https://ter.li/551ifu

Handsonwade